OR WAIT null SECS
Randi Hernandez was science editor at BioPharm International from September 2014 to May 2017.
August 27, 2015.
Novo Nordisk has big plans for its diabetes franchise. Yesterday the company announced that it would begin Phase IIIa trials for oral semaglutide, a protein product that can be administered orally, rather than via injection. In the first trial of the program-which is slated to begin in 2016-doses of 3 mg, 7 mg, and 14 mg of the long-acting glucagon-like peptide-1 (GLP-1) analog will be compared with a 100-mg dose of sitagliptin, another oral diabetes medication. The other parts of the program will roll out during 2016 as well.